Processa Pharmaceuticals, Inc. has successfully completed a public offering, raising $5 million to support its development of next-generation chemotherapeutic drugs aimed at improving efficacy and ...

Webcast Link: https://www.webcaster4.com/Webcast/Page/3023/49969 Mr. Ng will be available for one-on-one meetings throughout the conference. Investors can attend the ...

The MarketWatch News Department was not involved in the creation of this content. HANOVER, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage ...

Brings extensive experience in all phases of oncology drug development HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a ...

HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of ...

Dr. Young will be available for one-on-one meetings throughout the conference. For more information about the conference, click below:https://www.paradigmglobalevents ...

The MarketWatch News Department was not involved in the creation of this content. -- $452.5 million in total milestone payments -- $2.5 million in near-term payments -- Double-digit royalties on ...

Processa Pharmaceuticals shares were up over 140% so far. The company announced the completion of the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine. Markets are ...

The Dow Jones index closed higher by around 150 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...

Abstract Title: Adaptive Designed Eniluracil + Capecitabine Phase 2 Trial in Advanced or Metastatic Breast Cancer Patients Abstract Number: TPS1133 | Poster Board Number: 105b Session Title: Breast ...

Processa Pharmaceuticals Inc. (PCSA) shares have tumbled to a 52-week low, touching down at $0.8, marking a significant downturn for the micro-cap company currently valued at just $2.68 million.

HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next ...